Erythropoietin: A Candidate Neuroprotective Agent in the Treatment of Glaucoma

@article{Tsai2007ErythropoietinAC,
  title={Erythropoietin: A Candidate Neuroprotective Agent in the Treatment of Glaucoma},
  author={J. Tsai and B. Song and Li Wu and M. Forbes},
  journal={Journal of Glaucoma},
  year={2007},
  volume={16},
  pages={567-571}
}
Glaucoma is a progressive optic neuropathy that is the leading cause of irreversible blindness in the world. Although methods to lower intraocular pressure are the mainstay of glaucoma therapy, there are currently no available treatment modalities targeted at neuroprotection. Erythropoietin is a hematopoietic cytokine that has been shown to possess remarkable tissue-protective properties in preclinical models of neurodegeneration. As a result, there is a growing interest to explore the… Expand
Neuroprotection in glaucoma
TLDR
This review article looks into the current understanding of the pathophysiology of glaucoma, the importance of neuroprotection, the various possible pharmacological approaches for neuroprotection and evidence of current available medications. Expand
Erythropoietin as a novel therapeutic agent for atrophic age-related macular degeneration.
TLDR
Considering that erythropoietin (EPO) has antioxidant, anti-inflammatory, and neuroprotective properties, it is hypothesize that it can be developed as a novel therapeutic agent for the treatment of the atrophic form of ARMD. Expand
Biochemical changes and treatment in glaucoma
TLDR
The purpose of the article is to help in trying to understand the physiopathology of glaucoma and the efficacy of its treatments. Expand
Innovative IOP-Independent Neuroprotection and Neuroregeneration Strategies in the Pipeline for Glaucoma
  • J. Tsai
  • Medicine
  • Journal of ophthalmology
  • 2020
TLDR
Investigators are seeking to identify agents that are able to confer neuroprotection independent of IOP reduction, as well as providing for regeneration of nonviable RGCs and their axons to restore and/or maintain functional vision. Expand
The role of inflammation in the pathogenesis of glaucoma.
TLDR
This work reviews recent studies elucidating a possible role of low-grade inflammation as a causal factor in the pathogenesis of glaucoma and suggests other factors such as genetics, blood flow, and excitotoxicity should be considered. Expand
Use of erythropoietin in ophthalmology: a review.
TLDR
The role of EPO and its receptors in different tissues indicates that this hormone has extramedullary effects in other tissues, including the eye, and the biological roles of this hormone in the development and normal physiologic functions of the eye are explored. Expand
Recent advances in pharmacotherapy of glaucoma
TLDR
Future directions for the development of a novel therapy glaucoma may target glutamate inhibition, NMDA receptor blockade, exogenously applied neurotrophins, open channel blockers, antioxidants, protease inhibitors and gene therapy. Expand
Canadian Journal of Ophthalmology Lecture: translational research advances in glaucoma neuroprotection.
  • J. Tsai
  • Medicine
  • Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
  • 2013
TLDR
Translational research advances in neuroprotection may lead to future development of truly revolutionary therapies for glaucoma (e.g., neuroregeneration). Expand
Neuroprotection of Retinal Ganglion Cells
TLDR
In the Collaborative Normal-Tension Glaucoma Study, following medical or surgical treatment to achieve at least 30% reduction of intraocular pressure, 12% of patients experienced continued visual field loss secondary to optic nerve damage. Expand
Revisiting the role of erythropoietin for treatment of ocular disorders
TLDR
This review revisits the biological role of EPO in the development of the eye and the physiologic roles that it has, and discusses the clinical applications ofEPO for treatment of ocular disorders, modes of administration, EPO formulations, current clinical trials, and its future directions. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 92 REFERENCES
Pharmacologic neuroprotection with an inhibitor of nitric oxide synthase for the treatment of glaucoma
TLDR
A well-tolerated pharmacological inhibitor of NOS-2, perhaps orally or locally delivered, is a reasonable candidate for a neuroprotective agent for treating glaucoma. Expand
Erythropoietin as a novel neuroprotectant.
TLDR
Recent studies suggest that Epo is a potential novel neurotherapeutic agent and further clinical studies are warranted. Expand
Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis
TLDR
It is shown that, in rats suffering from myelin oligodendrocyte glycoprotein-induced optic neuritis, systemic application of erythropoietin (Epo) significantly increased survival and function of retinal ganglion cells (RGCs), the neurons that form the axons of the optic nerve. Expand
The Brain Erythropoietin System and its Potential for Therapeutic Exploitation in Brain Disease
TLDR
The safety profile and effectiveness of EPO in a wide variety of neurologic disease models make EPO a candidate compound for a potential first-line therapeutic for neurologic emergencies. Expand
Erythropoietin: a candidate compound for neuroprotection in schizophrenia
TLDR
It is demonstrated that peripherally applied recombinant human EPO penetrates into the brain efficiently both in rat and humans and enhances cognitive functioning in mice in the context of an aversion task involving cortical and subcortical pathways presumably affected in schizophrenia. Expand
Lessons for glaucoma from other neurodegenerative diseases: can one treatment suit them all?
TLDR
Although no single model can fully simulate human glaucoma or any other neurodegenerative disease, the availability of different models of optic nerve damage and the similarity of findings in the optic nerve and in other parts of the CNS have led to significant progress toward development of a cure for glAUcoma. Expand
Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice.
TLDR
Treatment with EPO at doses of 3000, 6000, and 12,000 U/kg body weight per week all prevented significant RGC loss, compared with untreated DBA/2J control animals, and suggest that EPO may be a potential therapeutic neuroprotectant in glaucoma. Expand
Effect of erythropoietin axotomy-induced apoptosis in rat retinal ganglion cells.
TLDR
A potential role for EPO as a therapeutic molecule against predominantly apoptotic neuronal cell death in the context of glaucoma or neurodegenerative diseases is supported and the PI-3-K/Akt pathway is delineated as the predominant mediator of EPO neuroprotection in this in vivo paradigm of neuronal cellDeath. Expand
Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy.
TLDR
The data suggest that erythropoietin is a potent ischemia-induced angiogenic factor that acts independently of VEGF during retinal angiogenesis in proliferative diabetic retinopathy. Expand
Protective Effect of Erythropoietin and Its Carbamylated Derivative in Experimental Cisplatin Peripheral Neurotoxicity
TLDR
The results widen the spectrum of possible use of erythropoietin and carbamylated erymorphic drugs as neuroprotectant drugs, strongly supporting their effectiveness. Expand
...
1
2
3
4
5
...